<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-76042</identifier>
<setSpec>0213-4853</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Neuronal death in amyotrofic lateral sclerosis</dc:title>
<dc:description xml:lang="en">Introduction. The recent failure of the clinical trial of ninocycline outlin es if the mechanism of development of the death neuronal in the sporadic amyotrophic lateral sclerosis (SALS) is different to that happens in models of transgenic mice with human mutations related with SOD (TgALS). Method. Differences on profile and intensity exist among the oxidative stress mechanisms between TgALS and SALS. Whereas the origin of apoptosis pathway in TgALS comes from the mithocondria and drives to caspase 9 with previous Bid and citocrome C discharge, in SALS, if apoptosis exists, that could proceed through activation ofFAS pathway by means of cathepsin B, or ¦Á-TNF, for microgl¨ªa activation or from cell cytosol. In FAS pathway, TNF-¦Á acts receptor ligands what drives to caspase 8 activation, although cathepsine B could act directly. Considering that the minocycline decreases Citocrome discharge, reducing executors caspases expression proceeding from intrinsic pathway, is justified its effectiveness inTgALS, but could not be explained if apoptosis in SALS was developed primarily on FAS pathway.Conclusions. Better knowledge of how cellular death occurs in SALS, could allow to suggest therapeuticoptions, and could permit to discriminate drugs that, showing effectiveness in TgALS, could not be beneficialsin SALS (AU)</dc:description>
<dc:creator>Garc¨ªa Ramos, R</dc:creator>
<dc:creator>Mat¨ªas-Guiu, J</dc:creator>
<dc:creator>Barcia, J. A</dc:creator>
<dc:creator>Gal¨¢n, L</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducci¨®n. El reciente fracaso del ensayo cl¨ªnico de minociclinaplantea si el mecanismo de desarrollo de la muerteneuronal en la esclerosis lateral amiotr¨®fica espor¨¢dica (SALS)es diferente al que ocurre en los modelos de rat¨®n transg¨¦nicocon mutaciones humanas relacionadas con SOD (TgALS).M¨¦todo. Existen diferencias entre los mecanismos deestr¨¦s oxitativo en TgALS y SALS de perfil e intensidad. Mientrasla apoptosis en TgALS procede primariamente de la mitocondriay conduce a la activaci¨®n de caspasa 9 previa descargade Bid y citocromo C, en la SALS si existiera apoptosisse podr¨ªa plantear la hip¨®tesis que pudiera proceder a trav¨¦sde la activaci¨®n de la v¨ªa del FAS, a trav¨¦s de la catepsina Bo del TNF-¦Á, que podr¨ªa provenir de la activaci¨®n de la microgliao con origen citoplasm¨¢tico. En la v¨ªa del FAS, elTNF-¦Á act¨²a como ligando del receptor FAS, lo que conducir¨¢a la activaci¨®n de caspasa 8, aunque la catepsina B podr¨ªaactuar directamente sobre ella. Considerando que laminociclina produce la disminuci¨®n de la descarga de citocromoC dificultando la producci¨®n de las caspasas ejecutorasa trav¨¦s de la v¨ªa intr¨ªnseca, se justifica su eficacia enTgALS, pero no as¨ª si en la apoptosis en la SALS si se confirmasu desarrollo primariamente en la v¨ªa del FAS.Conclusiones. Un mejor conocimiento de c¨®mo se producela muerte celular en la SALS puede sugerir opcionesterap¨¦uticas y discriminar entre aquellas que, aun mostrandoeficacia en TgALS, pueden no serlo en SALS (AU)</dc:description>
<dc:source>Neurologia;23(8): 518-529, oct. 2008. ilus</dc:source>
<dc:identifier>ibc-76042</dc:identifier>
<dc:title xml:lang="es">Muerte neuronal en la esclerosis lateral amiotr¨®fica</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d30204</dc:subject>
<dc:subject>^d704^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30827</dc:subject>
<dc:subject>^d32101</dc:subject>
<dc:subject>^d9099^s22073</dc:subject>
<dc:subject>^d23222</dc:subject>
<dc:subject>^d704^s22033</dc:subject>
<dc:subject>^d704^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>200810</dc:date>
</metadata>
</record>
</ibecs-document>
